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ABSTRACT 
Several C-β-D-glucopyranosyl azoles have recently been unravelled among the most potent 
glycogen phosphorylase (GP) catalytic site inhibitors discovered to date. Towards further 
exploring their translational potential, ex-vivo experiments have been performed for their 
effectiveness in reduction of glycogenolysis in hepatocytes. New compounds for these 
experiments were predicted in silico where, for the first time, effective ranking of GP catalytic 
site inhibitor potencies using the MM-GBSA method has been demonstrated. For a congeneric 
training set of 27 ligands, excellent statistics in terms of Pearson (Rp) and Spearman (Rs) 
correlations (both 0.98), predictive index (PI = 0.99) and AU-ROC (0.99) for predicted versus 
experimental binding affinities were obtained, with ligand tautomeric/ionization states 
additionally considered using DFT calculations. Seven 2-aryl-4(5)-(β-D-glucopyranosyl)-
imidazoles and 2-aryl-4-(β-D-glucopyranosyl)-thiazoles were subsequently synthesized and 
kinetics experiments against rabbit muscle GPb revealed new potent inhibitors with best Ki-s 
in the low µM range (5c = 1.97 µM; 13b = 4.58 µM). Ten C-β-D-glucopyranosyl azoles were 
then tested ex-vivo in mouse primary hepatocytes. Four of these (5a-c and 9d) demonstrated 
significant reduction of glucagon stimulated glycogenolysis (IC50 = 30-60 µM). Structural and 
predicted physicochemical properties associated with their effectiveness was analysed, with 
permeability related parameters identified as crucial factors. The most effective ligand series 5 
contained an imidazole ring and the calculated pKa (Epik: 6.2; Jaguar 5.5) for protonated 
imidazole suggests that cellular permeation through the neutral state is favoured, while within 
the cell there is predicted more favourable binding to GP in the protonated form.    
 
Keywords: C-glycoside, imidazole, thiazole, glycogen phosphorylase inhibitor, permeability, 
MM-GBSA 
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INTRODUCTION 
Diabetes mellitus, characterized by hyperglycemia, is a chronic severe multiform disease with 
considerable socio-economic consequences. Recent WHO figures reveal an increase of cases 
from 108 million people in 1980 to 422 million in 2014, affecting ~8.5% of the global adult 
population.1 This number may even be an underestimate due to methodological uncertainties 
as well as undiagnosed cases.2 Diabetes has become one of the largest contributors to mortality 
due to long term complications such as retinopathy, neuropathy, nephropathy, but particularly 
cardiovascular diseases. Type 2 diabetes (T2D) is the most common form and involves 
abnormal insulin secretion and/or insulin resistance. Therapy for lowering blood glucose in 
T2D is by diet, exercise, and oral anti-hyperglycemic agents. In spite of the availability of 
different classes of anti-hyperglycaemic drugs,3 treatments are often unable to achieve the 
required degree of glucose control for a large number of patients.4 
 
In T2D, glucose production by the liver is elevated and is contributing to the high blood glucose 
levels. Liver glycogenolysis releases glucose from glycogen into the bloodstream, with 
glycogen phosphorylase (GP; EC 2.4.1.1) the rate-limiting enzyme in this pathway.5 Due to its 
key role in glycogen metabolism, GP inhibition has become a validated approach in the 
development of new T2D treatments.6 Importantly, GP inhibitors (GPIs) also have revealed 
potential for treatment of other conditions such as myocardial and cerebral ischemias, and 
cancer.7, 8   
 
Although several structural classes of GPIs have been reported,9-11 glucose analogues binding 
at the catalytic site (competitive reversible inhibitors) have been the most explored10, 12 and 
structure based inhibitor design efforts are greatly facilitated by the many solved 
crystallographic protein-ligand complexes.13 Recently reported C-β-D-glucopyranosyl azoles 
(Table 1, 1-9) comprise some of the most effective GPIs.14 Their aromatic R groups, 
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particularly 2-naphthyl, enhance inhibitor potency by exploiting favourable interactions in the 
β-cavity of the catalytic site.10, 12 Of particular interest, imidazoles14 5 and 1,2,4-triazoles14 9 
have revealed inhibitors such as 5a,b and 9b with Ki-s in the nanomolar range. Compound 5b 
is the most potent catalytic site inhibitor discovered to date. The efficacy of GPIs on 
glycogenolysis in cellular models15-18 and blood glucose control in vivo18-21 has been 
demonstrated for some inhibitors. However, the lack of such data for potent GPIs of the C-β-
D-glucopyranosyl azole type limits the potential for eventual translation into the clinic and the 
actual benefit of the patient, and has motivated the current work. 
 
In this study, in silico screening has been performed for the new C-β-D-glucopyranosyl azoles 
10-13, as well as ligands 3b,c and 5c also previously not synthesized or evaluated as GP 
inhibitors (Table 1). Initial docking experiments were followed by post-docking molecular 
mechanics – generalized Born surface area (MM-GBSA)22 binding free energy (BFE) 
predictions, with the approach first validated for a training set of 27 ligands. Seven candidates 
were selected for synthesis and kinetics experiments against GP performed to determine the 
true potencies. Ten C-β-D-glucopyranosyl azole GPIs with four different heterocycles and 
different R groups then underwent ex-vivo experiments in hepatocytes. These inhibitors were 
selected to analyse structural features and predicted physicochemical properties that may 
govern their efficacy for reduction of glycogenolysis at the cellular level. 
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Table 1. C-β-D-Glucopyranosyl azole type inhibitors (ref.14 and references within) of rabbit muscle 
glycogen phosphorylase b (Ki [μM]) and the target compounds for this study.  
  Aromatic R groups 
 
    
 Het a b c 
1 
 
No inh. at 625 µMa No inh. at 625 µMa NSc 
2 
 
No inh. at 625 µMa No inh. at 625 µMa NSc 
3 
 
400a -b -b 
4 
 
310a 158a NSc 
5 
 
0.28a 0.031a -b 
6 
 
10% inh. at 625 µMa 10% inh. at 625 µMa 10% inh. at 625 µMa 
7 
 
10% inh. at 625 µMa 38a No inh. at 625 µMa 
8 
 
64a 11.6a 19a 
9 
 
7a 0.41a 11.523 
 
    
10 11 12 13 
 Target compounds of this study with R groups a-c. 
a Member of training set ligands for calculations. For full list of ligands see Table S1. 
b Existing heterocyclic linkers with the indicated additional R substituent studied in this work. 
c Not studied. 
 
RESULTS AND DISCUSSION 
In Silico Screening Studies 
Model Validation 
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A training set of 27 previously studied β-D-glucopyranosyl derivatives with twelve different 5-
membered heterocyclic linkers (Table S1) was first used to validate an in silico screening 
protocol. These GP inhibitors had a good range of Ki values, from 0.031 µM to no inhibition. 
‘Activity’ was defined in terms of inhibitor potency throughout. The performance of docking 
(Glide-SP and –XP24, GOLD-ChemPLP25) and post-docking using MM-GBSA (Prime24) with 
respect to accurate prediction of relative ligand activities for the training set ligands was 
analyzed in a statistical manner.23 Correlation between predicted and experimental activities 
was measured using Pearson (RP) and Spearman (RS) correlation coefficients. Rp takes into 
account the absolute differences between activity values within each set (predicted and 
experimental), whereas for RS, only the activity rank is important since in each set of data the 
values are converted to a rank order. The ‘predictive index’ (PI)26 was considered as a measure 
of how well  a model differentiates inhibitors that have larger differences in potencies. A PI 
value (range -1 to +1) closer to +1 indicates better performance. Finally, the area under the 
ROC curve (AU-ROC) values are reported as the probability (range 0 to 1) of active 
compounds being ranked higher than inactive compounds. For this, a threshold Ki < 20 μM 
was used to define ‘actives’, leading to n = 7 actives in the set of N = 27 compounds. 
 
The results of this statistical analysis are shown in Table 2. Comparing the different docking 
methods for predicted (GlideScores for Glide and ChemPLP fitness scores for GOLD) versus 
experimental (BFEs) binding affinities, only modest statistical performance was observed. 
Glide-SP performed best (RP = 0.70, Rs = 0.61, PI = 0.63), with an AU-ROC value of 0.83 
indicating reasonably good potential to recognise inhibitors with Ki’s < 20 μM threshold value. 
Overall, however, the statistics reflect inferior performance of docking methods for these 
ligands compared to a recent GP in silico screening study of 3-(β-D-glucopyranosyl)-5-
substituted-1,2,4-triazole derivatives.23  
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Significantly enhanced performance was achieved by refining the docking output using post-
docking Prime MM-GBSA calculation of BFEs (∆𝐺𝑏𝑖𝑛𝑑
′ ): 
                                              ∆𝐺𝑏𝑖𝑛𝑑
′ = ∆𝐸𝑀𝑀 + ∆𝐺𝑠𝑜𝑙𝑣                                                Eq. (1) 
ΔEMM represents the molecular mechanics energy difference (internal, electrostatic and van der 
Waals) between the protein-ligand bound and unbound states calculated using the OPLS3 
forcefield. ΔGsolv is the corresponding solvation free energy change on binding calculated using 
a variable-dielectric generalized Born solvation model. The resulting BFEs were calculated 
both with and without incorporation of ligand reorganisation (strain) energy on binding (protein 
constrained to be rigid). Best statistical performance was obtained using the Glide-SP poses as 
input. Good statistics were obtained with ligand strain included (RP = 0.85; RS = 0.74; PI = 0.85 
and AU-ROC = 0.95) but even better statistics without ligand strain were observed (RP = 0.93; 
RS = 0.84; PI = 0.92 and AU-ROC = 0.98).  This best performing Prime MM-GBSA model 
(with and without strain) using Glide-SP poses is referred to as Model 1 (Table 2).  
 
Table 2. For the training set of twenty-seven β-D-glucopyranosyl azoles (Table S1), statistical 
analysis of the agreement between predicted and experimental activities as described in the text.a  
       
 Pearson Correlation Spearman Correlation     
Method RP p-value t-value RS p-value t-value PI p-value AU-ROC p-value 
Docking           
Glide-SP 0.70 0.003 3.62 0.61 0.012 2.89 0.63 0.0084 0.83 0.0047 
Glide-XP 0.51 0.043 2.23 0.44 0.087 1.83 0.65 0.0075 0.73 0.0406 
GOLD-ChemPLP  0.64 0.007 3.13 0.56 0.024 2.52 0.63 0.0091 0.79 0.0132 
Prime 
MM-GBSAb,c 
          
Glide-SP poses 
(Model 1) 
0.85 
 (0.93) 
0.000 
(0.000) 
6.07 
(9.27) 
0.74 
(0.84) 
0.001 
(0.000) 
4.06 
(5.82) 
0.85 
(0.92) 
0.0000 
(0.0000) 
0.95 
(0.98) 
0.0001 
(0.0000) 
Glide-XP poses 0.76 
 (0.71) 
0.001 
(0.002) 
4.38 
(3.81) 
0.59 
(0.54) 
0.016 
(0.032) 
2.74 
(2.39) 
0.76 
(0.70) 
0.0012 
(0.0029) 
0.86 
(0.85) 
0.0017 
(0.0026) 
GOLD-ChemPLP 
poses 
0.80 
 (0.77) 
0.000 
(0.001) 
5.01 
(4.53) 
0.59 
(0.57) 
0.016 
(0.021) 
2.74 
(2.60) 
0.76 
(0.73) 
0.0019 
(0.0012) 
0.86 
(0.86) 
0.0017 
(0.0021) 
Refined  
MM-GBSAc,d  
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Model 2e 0.93 
 (0.98) 
0.000 
(0.000) 
9.50 
(16.61) 
0.91 
(0.98) 
0.000 
(0.000) 
8.47 
(16.94) 
0.95 
(0.99) 
0.0000 
(0.0000) 
0.97 
(0.99) 
0.0000 
(0.0000) 
Model 3f 0.84 
 (0.91) 
0.000 
(0.000) 
5.73 
(8.03) 
0.70 
(0.80) 
0.003 
(0.000) 
3.67 
(5.04) 
0.83 
(0.89) 
0.0001 
(0.0001) 
0.94 
(0.96) 
0.0001 
(0.0000) 
Model 4g 0.93 
 (0.97) 
0.000 
(0.000) 
9.16 
(14.95) 
0.91 
(0.97) 
0.000 
(0.000) 
8.15 
(15.08) 
0.95 
(0.98) 
0.0000 
(0.0000) 
0.96 
(0.97) 
0.0000 
(0.0000) 
a
 Best statistics for docking, MM-GBSA and refined MM-GBSA methods are highlighted in bold italics. For the correlation 
coefficients Rp and Rs, p-values are derived from the t-distribution (t-values) for n-2 degrees of freedom. P-values for PI were 
derived from a null distribution created from bootstrapping (n = 1,000,000) 'active' group allocation, and p-values for AU-ROC 
were derived from the Wilcoxon-Rank-Sum distribution since W = AU-ROC × n × (N - n).27 W is the Wilcoxon statistic (also 
known as Mann-Whitney U), N is the number of ligands (27) and n is the number of actives (7). P-values < 0.05 in all cases indicate 
statistical significance. All statistics were calculated using the R program.28 
b
 Calculated using Prime and Eq. (1). 
c 
Values are with 
ligand strain included but with values without ligand strain given in parentheses. 
d
 Using the best Prime MM-GBSA model with 
Eq.(1) from the Glide-SP poses (Model 1) as a benchmark for improvement. 
e
 Model 1 data with tautomeric correction (Eq. (1)). f 
Model 1 data with entropy included (Eq. (2)). g Model 1 data with tautomeric correction & entropy included (Eq. (2)). 
 
As predicted by LigPrep24, there were three heterocyclic linkers (pyrazole 3, imidazole 5, and 
1,2,4-triazole 9) in the training set and one heterocycle (imidazole 13) among the target 
compounds with the potential to form tautomers (Table 3). The imidazole based ligands 5 and 
13 were also predicted to have potential to be protonated. Until now, we have taken the best 
predicted ∆𝐺𝑏𝑖𝑛𝑑
′  value of a ligand as the predicted value from the different possible 
ionization/tautomeric states. However, to consider more accurately the potential tautomeric 
effects on binding, DFT gas and solution phase calculations were performed to establish the 
most favourable tautomeric states of 3, 5, 9 and 13 ligands in the unbound state (Table 3). 
Additionally, the potential for protonation (+1 charge) of the imidazole based ligands 5 and 13 
was probed using Epik and Jaguar pKa calculations.24 
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Table 3. Relative gas and solution phase energies (in parentheses) of the tautomeric forms 
of relevant ligands calculated using DFT at the M06-2X/6-31+G* level of theory with 
water solvation effects included via a Solvation Model 8 (SM8) continuum treatment.a 
Heterocyclic 
compound 
Tautomer 1 Tautomer 2 Tautomer 3 
3b,c   
- 
0.0 (0.0) 3.0 (2.3) - 
5b,c 
  
- 
0.0 (0.0) 0.6 (2.1) - 
9b 
   
0.0 (0.0) 3.2 (1.6) 6.1 (6.2) 
13c   
- 
0.0 (0.0) 4.8 (4.6) - 
a As a model for the aromatic R groups (Table 1), a phenyl group was used. b Training set ligand 
heterocycle. c Predicted target ligand heterocycle. 
 
The most favourable binding state of the imidazole 5 ligands was consistently predicted as the 
protonated (+1) state (c.f. 5b binding in Figure 2(A)). In fact, considering only neutral states of 
the 5 ligands, the RP value of 0.93 for Model 1 without strain, for example, decreases to 0.74. 
The calculated pKa value of protonated 5 with R = phenyl was ~ 6 (Epik: 6.2; Jaguar: 5.5) 
implying that these ligands will be mainly neutral in solution, but partial protonation means 
that this favourable binding will be facilitated. For the 1,2,4-triazole linker (9), only neutral 
state ligands were predicted by LigPrep and the most stable free state tautomer as calculated 
by DFT (tautomer 1, Table 3) was also the most favourable in terms of ∆𝐺𝑏𝑖𝑛𝑑
′ . For pyrazole 
3, however, binding (∆𝐺𝑏𝑖𝑛𝑑
′ ) through tautomer 2 was preferred but the most stable free state 
was tautomer 1 (~2-3 kcal/mol). Significantly, the best performing Prime MM-GBSA model 
using Glide-SP poses (Model 1) had ligand 3a (noting that 3b and 3c were targets for 
10 
 
prediction) as an outlier in the plots of ∆𝐺𝑏𝑖𝑛𝑑
′  against the experimental BFEs (Figure 1(a)). 
Taking instead the ∆𝐺𝑏𝑖𝑛𝑑
′
 value for tautomer 1 led to further improvement in performance 
statistics (Model 2 – data from Model 1 but including tautomeric correction, Table 2). For 
Model 2, excellent values for each metric with ligand strain (RP = 0.93; RS = 0.91; PI = 0.95 
and AU-ROC = 0.97) and particularly without ligand strain correction (RP = 0.98; RS = 0.98; 
PI = 0.99 and AU-ROC = 0.99) were now obtained (Figure 1(b)). 
 
 
Figure 1. Scatter plots of predicted ∆𝐺𝑏𝑖𝑛𝑑
′
 values (Eq. (1)) against experimental binding free 
energies obtained using MM-GBSA without ligand strain (a) before tautomeric correction 
(Model 1) and (b) after tautomeric correction (Model 2) (c.f. Table 2). Tautomeric correction 
for 3a is displayed via an open circle. The lines drawn on the plots are from a Type II (standard 
major axis) regression model which allows error in both variables29 and is appropriate in this 
case.  
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We additionally probed the effect of inclusion of entropy effects (∆𝑆𝑀𝑀) as per ∆𝐺𝑏𝑖𝑛𝑑 (Eq. 
(2)), accounting for the loss of ligand vibrational, rotational and translational entropy on 
binding calculated using the Rigid Rotor Harmonic Oscillator approximation with the OPLS3 
forcefield.  
                                              ∆𝐺𝑏𝑖𝑛𝑑 = ∆𝐸𝑀𝑀 + ∆𝐺𝑠𝑜𝑙𝑣 − 𝑇∆𝑆𝑀𝑀                             Eq. (2) 
The effect of its inclusion on the performance statistics was minimal (Models 3 and 4, Table 
2), which could be attributed to the similarity among this congeneric series of ligands. Entropy 
inclusion is often a source of uncertainty in calculations of this type but in cases does improve 
quality of results.22, 30, 31 Based on the statistics (Table 2), we considered the MM-GBSA Model 
2 (Glide-SP poses as input; tautomeric correction; neglection of entropy effects) the most 
efficient for predictions on the target compounds (Table 1). This is the first time that the 
endpoint MM-GBSA method has been demonstrated as an effective method for ranking of 
congeneric series of ligands for the GP catalytic site. Previous comparisons of the effectiveness 
of MM-GBSA and MM-PBSA revealed that the prediction accuracies can be quite different 
for different protein families.32  
  
Screening of Target Compounds 
The full set of predicted ∆𝐺𝑏𝑖𝑛𝑑
′  values for the target compounds using Model 2 are reported in 
Table S2. As benchmarks for comparison, the predicted ∆𝐺𝑏𝑖𝑛𝑑
′  value ranges for the training 
set active compounds (Ki’s < 20 µM) were -66.5 – -87.9 kcal/mol and -71.7 – -92.4 kcal/mol 
with and without ligand strain corrections included, respectively.  
 
The 1-naphthyl substituted imidazole linker (5c) was predicted best among the target 
compounds with very good ∆𝐺𝑏𝑖𝑛𝑑
′  values of –85.2 kcal/mol and –93.8 kcal/mol with and 
without ligand strain included, respectively, and was immediately a synthetic candidate. It is 
predicted to bind in the protonated state of the heterocycle (Figure 2(B)). While none of the 
12 
 
new heterocyclic scaffolds (10-13) from Table 1 were predicted to produce more potent 
inhibitors than the pre-existing most effective heterocycles (imidazole 5 and 1,2,4-triazole 9), 
the imidazole 13 did yield reasonably good ∆𝐺𝑏𝑖𝑛𝑑
′ values. Compounds 13a, 13b and 13c had 
∆𝐺𝑏𝑖𝑛𝑑
′ values of –72.4, –78.5 and –79.5 kcal/mol with ligand strain, respectively, and –78.9, –
86.7 and –88.9 kcal/mol without ligand strain included, respectively. The predicted binding 
modes of 13b and 13c to GPb are shown in Figure 2(D) and 2(E), respectively, where, like the 
isomeric imidazole 5c, the predicted most favourable binding state of the heterocycle is 
protonated. The calculated pKa value of protonated 13 with R = phenyl (Epik: 6.1; Jaguar: 5.4) 
supports partial protonation for binding in this state. In terms of the other ligands screened, the 
tautomeric corrected ∆𝐺𝑏𝑖𝑛𝑑
′  values were poor for 3b and 3c (e.g. ~ –55 kcal/mol with ligand 
strain), possibly in line with the existing Ki of 400 µM for 3a33, and the other heterocycles (10-
12 ligands) were predicted only borderline close to active (Ki’s < 20 µM). We did, however, 
consider the thiazole (12) based analogues interesting given the potential of sulphur to improve 
cell permeability and due to sulphur atom occurrence in a large number of marketed drugs, 
particularly in the form of heterocycles.34 The predicted binding of 12b is shown in Figure 
2(C). All things considered, imidazole 5c, and imidazoles 13b and 13c appeared the most 
attractive candidates from the in silico screening and selected for synthesis, together with 12a-
c despite their lower predicted potency rankings (Table S2) to study the effects of a sulphur 
based heterocycle. For comparative purposes, the R = phenyl analogue 13a was also chosen.  
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Figure 2. Predicted binding interactions of (A) 5b, (B) 5c, (C) 12b, (D) 13b and (E) 13c with 
glycogen phosphorylase b as calculated using MM-GBSA. For 5b and 5c, the protonated 
heterocycle exploits a favourable hydrogen bond interaction with His377 O. The other NH is 
close to but not within hydrogen bonding distance of the Asp283 sidechain carboxylate but 
exploits ion-ion interactions. RMSD (heavy atoms) of the predicted 5b position compared to 
its native crystallographic complex (PDB code: 5JTU) was just 0.250 Å. For 13b and 13c, 
compared to isomeric 5b and 5c, the heterocycles and NH interactions with His377 O are 
weaker (distances 3.4–3.6 Å). The ligands instead form hydrogen bond and ion-ion interactions 
with the Asp283 sidechain carboxylate. Also, the aromatic groups occupy different positions 
in the β-cavity to imidazole 5 type ligands. For 12b, the thiazole does not exploit any direct 
hydrogen bond interactions with GP, only a weak heterocycle CH to His377 O interaction, but 
the 2-naphthyl moiety extends deep into the β-cavity.  
 
 
Syntheses  
For the preparation of 2-aryl-4-(β-D-glucopyranosyl)-thiazoles 12 (Scheme 1) glucosyl 
bromomethyl ketone 1435 was cyclized with thiobenzamide and naphthalene-2- and -1-
14 
 
thiocarboxamide in anhydrous DMF to afford the protected thiazoles 15a-c, respectively. 
Debenzoylation of 15a-c was carried out by the Zemplén protocol providing the deprotected 
derivatives 12a-c in very good yields.  
 
When compound 14 was treated with arene carboxamidines in a THF-H2O solvent mixture in 
the presence of K2CO3 the cyclisation was accompanied by hydrolytic cleavage of the 2’-O-
benzoyl group resulting in partially protected derivatives 16a-c in moderate yields. 
Subsequently, complete debenzoylation of 16a-c was accomplished by the Zemplén method to 
give excellent yields of the final products 13a-c.  
 
Scheme 1. Reagents and conditions: a) dry DMF, 140 °C; b) 4 equiv. K2CO3, THF-H2O (4 : 
1), rt; c) ~ 1M NaOMe in MeOH, rt.; d) 2 equiv. K2CO3, THF-H2O (4 : 1), rt; e) 40 equiv. 
EtSH, 20 equiv. BF3.Et2O, dry CH2Cl2, rt. 
 
The synthesis of 4-(1-naphthyl)-imidazole derivative 5c was performed by the cyclization of 
formamidine salt36, 37 17 with the corresponding α-bromo-ketone under basic conditions to give 
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the protected imidazole 18 in acceptable yield. Cleavage of the O-benzyl groups in 18 was 
effected by treatment with ethanethiol in the presence of BF3.Et2O to obtain the test compound 
5c in good yield. 
 
Kinetics Results 
The new compounds were assayed against rmGPb as described earlier35 and the inhibition 
constants are summarized in Table 4. Consistent with glucose-derived inhibitors studied so far, 
these new compounds also proved competitive catalytic site inhibitors as indicated by the 
Dixon plots of the primary data (see Supporting Information); that 12b and 13a may also bind 
at a secondary site cannot be confirmed or fully discarded from Dixon plots. The most potent 
predicted target compound 5c was also the most potent experimentally (Ki = 1.5 µM), although 
it is not as potent as its previously reported analogues, 5a (Ki = 0.28 µM) and 5b (Ki = 0.031 
µM). The potencies of the isomeric imidazole 13b (Ki = 4.58 µM) was in line with expectations 
from the predictions being a low micromolar inhibitor, but 13a (Ki = 68.6 µM) and 13c (Ki = 
71.1 µM) were less potent than expected. Overprediction of 1-naphthyl analogues inhibitor 
potencies was therefore observed for this particular R group that was less well represented in 
the model validation training set ligands (Table S1). Thiazole 12b (Ki = 26.2 µM) was 
borderline close to our defined threshold Ki < 20 µM for activity, while its phenyl 12a (Ki = 
326 µM) and 1-naphthyl 12c (Ki = 540 µM) analogues were much weaker inhibitors.   
 
Table 4. Inhibitory effect of the new C-β-D-
glucopyranosyl heterocycles against rabbit muscle GPb  
Compound Ki [µM]  
 
5c 
1.97 
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12a 
326* 
 
12b 
26.2 
 
12c 
540* 
 
13a 
68.6 
 
 
13b 
4.58 
 
13c 
71.1 
*Calculated from the IC50 value by a web-based tool.38 
 
Cellular and Pharmacokinetic Evaluation 
Based on the kinetics results and to allow analysis of inhibitor structural features that may 
influence efficacy at the cellular level, compounds 5a, 5b, and 9b from Table 1, 5c, 12b, 13a, 
13b and 13c from Table 4, and 9d and 9e shown in Table 5 were chosen (Ki-s in the range of 
0.03 – 71 µM) to study their effects on glycogenolysis in hepatocytes.  The pharmacokinetic 
profiles of the compounds were also predicted using QikProp 4.9.24 
 
The IC50 values for cellular inhibition of glycogenolysis of the 10 compounds are shown in 
Table 5 together with the predicted absorption, distribution, metabolism and excretion 
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(ADME) properties.  Glycogenolysis was determined from glucose release in the presence of 
glucagon to promote phosphorylation (activation) of GP and fractional inhibition of glucose 
production by the compounds (at 100 µM) is shown in Figure 3. 1,4-Dideoxy-1,4-imino-D-
arabinitol (DAB) was used as a reference compound because of its high potency (IC50  of ≤ 1 
µM) at inhibiting phosphorylated and non-phosphorylated forms of GP and known efficacy at 
the cellular level (Figure 3).39, 40 Unlike glucose analogues which stabilize the T-conformation, 
DAB stabilizes the R-conformation and favours conversion of GPb to GPa,41, 42 however, it 
inhibits GPa to GPb similarly.43 DAB also inhibits glucosidase including the glycogen 
debranching enzyme but with 10-fold lower affinity compared with GPa and GPb.43, 44 
Compounds 5a and 5b showed the highest cellular efficacy (IC50 of 30-40 µM), followed by 
5c and 9d (IC50 of ~ 60 µM).  The other compounds (9b, 9e, 12b, 13b, 13c) except 13a caused 
significant inhibition of glucose release at 100 µM but with an IC50 > 100 µM. Some 
compounds including 9d caused release of lactate dehydrogenase at concentrations > 100 µM, 
which is suggestive of possible counter-effects of compromised calcium homeostasis on 
glycogenolysis at high concentrations ≥ 100 µM.   
18 
 
 
Figure 3. Glucose release from mouse hepatocytes incubated with glucagon and the 
compounds indicated in comparison with DAB used as the reference compound.  A.  Fractional 
inhibition by compounds determined at 100 µM, expressed as percentage of control incubations 
with glucagon, dashed line indicates glucose production in the absence of glucagon. B.   
Comparison with DAB at varying compound concentration.  Glucose release in the absence of 
glucagon was 58 ± 3%.  Means ± SEM, n=6-8. 
 
Ligand series 5 were therefore the most effective for both purified enzyme GP inhibition (Ki’s 
= 0.031 – 1.97 µM) and also in the cellular assays (IC50’s ~ 30 – 60 µM). These ligands will 
be predominantly neutral (predicted pKa ~ 6 for protonated imidazole 5a) in the free state and 
19 
 
favour permeability. Within the cell, the protonated form was predicted to bind strongest at 
GP. Considering Lipinski's rules of five and Jorgensen's rule of three for oral bioavailability, 
calculated properties for 5a-c are consistent (no violations) with favourable absorption and 
permeability (assuming the inhibitors are not substrates for biological transporters). Veber’s 
rules45 consider other parameters for description of drug-likeness with too many rotatable 
bonds (>10) and too large a polar surface area (PSA > 140 Å2) bad for absorption and 
permeation. These rules were also passed for the 5 series of compounds. For the isomeric 
imidazole 13 series, IC50’s were > 100 µM in the cellular assays; however, the purified enzyme 
inhibitions (Ki’s = 4.58 – 71 µM) were also less for 13a-c (compared to 5a-c). For 13a, the not 
significant cellular inhibition could in part stem from its lower log P of –0.09 (theoretical log 
D of –0.12 at pH 7).     
 
Of the 9 series, both 9b and 9e had IC50 > 100 µM despite their potent inhibition of the free GP 
enzyme (Ki = 0.41 and 4.42 µM, respectively). However, 9d (Ki = 1.19 µM) was one of the 
most effective compounds at the cellular level (IC50 = 57 µM), indicating that differences in 
compound physicochemical properties arising from the R group substitutions could be 
important. Comparing 9b (Ki = 0.41 µM) first with 5b (Ki = 0.031 µM), both of which have R 
= 2-naphthyl and are two of the most potent GPIs known to date, the lack of cellular efficacy 
for 9b (IC50 > 100 µM) compared to 5b (IC50 = 28 µM) could be in part attributed to its less 
favorable lipophilicity (log P = -0.01 versus 0.63) and PSA (136 Å2 versus 121 Å2), that is, 
properties important for cellular permeability. On the other hand, the cellular efficient 9d (IC50 
= 57 µM) with R = 2-fluorenyl has a predicted log P of 0.57 close to that of ligand 5b, 
reinforcing permeability as a key parameter. In further agreement, the other cellular inefficient 
9e ligand (IC50 > 100 µM) contains an anionic (carboxyl) 2-naphthyl substituent, and had one 
violation each of Lipinski’s (HBD = 6), Jorgensen’s (Caco-2 = 1.5 nm s-1) and Veber’s (PSA 
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= 187 Å2) rules, violations consistent with poor permeability. The cellular performance of 
thiazole derivative 12b (IC50 > 100 µM) was disappointing despite its predicted parameters 
favorable for permeability. There was one violation of Jorgensen’s rules (NPM = 7) and it is 
possible that metabolism could be the more important factor in this case.     
 
 
 
Potential permeability issues for glucose analogues have been highlighted in the past.15, 23, 46, 47 
Here, log P in particular was identified as an important benchmark, but with exceptions such 
Table 5. IC50 results for glucagon-stimulated glycogenolysis in mouse hepatocytes together with ADME property predictions for the studied 
glycogen phosphorylase inhibitors. Purified enzyme inhibition constants (Ki’s) are also shown for comparison.[a] 
Ligand Lipinskis’s Rule of Five and Violations (V)[b]   
Jorgensen’s Rule of Three & 
Violations (V)[b] 
  
Veber’s Rules & 
Violations (V)[b] 
  
  
Mr 
[Da] 
HBD[c] HBA[d] log P(o/w) 
V 
Caco-2  
[nm s-1] [e] 
log S NPM[f] 
V 
PSA [Å2][g] NROT[h] 
V 
Ki 
GPb 
IC50 
Cellular 
(<500) (≤5) (≤10) (<5) (>22) (>-5.7) (<7) (<140 Å2) (≤10) (µM)     (µM) 
5a 306.3 5 7 -0.15(-0.16)[i] 0 117.0 -2.8 6 0 121 5 0 0.28 37±14 
5b 356.4 5 7 0.63 (0.62)[i]               0 112.9 -3.7 6 0 121 5 0 0.031 28 ± 8 
5c 356.4 5 7 0.57 (0.56)[i] 0 116.5 -3.5 6 0 122 5 0 1.544 63±6 
9b 357.4 5 8 -0.01 0 58.8 -3.5 6 0 136 5 0 0.41 >100 
9d 395.4 5 8 0.57 0 58.8 -4.3 7 1 137 5 0 1.19 57±12 
9e 401.4 6 10 -0.67 1 1.5* -3.5 6 1 187 6 1 4.42   >100 
12b 373.4 4 6 1.21 0 182.8 -4.1 7 1 106 5 0 23   >100 
13a 306.3 5 7 -0.09 (-0.12)[i] 0 131.1 -2.9 6 0 120 5 0 37 NS[j] 
13b 356.4 5 7 0.71 (0.68)[i]  0 130.8 -3.8 6 0 120 5 0 5.4 >100 
13c 356.4 5 7 0.68 (0.65)[i] 0 135.3 -3.7 6 0 120 5 0 93 >100 
Range
[k] 
130-
725 
0-6 02-20 -2-6.5' - 
<25 poor;              
> 500 
great 
-6.5-
0.5 
1-8 - 7-200 0-15 - -  
[a] ADME properties were calculated using Qikprop 4.9; predicted properties outside the range for 95% of known drugs are indicated with an 
asterisk (*). [b] Rules as listed in the columns, with any violations of the rules highlighted in bold italics. [c] Number of hydrogen bond donors. [d] 
Number of hydrogen bond acceptors. [e] Caco-2 cell permeability. [f] Number of primary metabolites. [g] PSA represents the van der Waals (polar) 
surface areas of N and O atoms. [h] Number of rotatable bonds.  [i] Theoretical log D at pH 7 based on QM calculated Jaguar pKa is given in 
parentheses. [j] Not significant. [k] Range for 95% of known drugs - QikProp User’s Manual.  
 
9d 23 
 
9e 23 
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as for 12b. The log P range of the ten compounds tested was -0.67 – 1.21 which is outside the 
proposed log P (~2-4) sweet spot range in medicinal chemistry,48 and is proposed as a target 
range in future inhibitor design efforts. Further, a recent study of D-glucopyranosylidene-spiro-
isoxazolines revealed that the O-peracetylated form of its glucose unit in the 2-naphthyl 
analogue showed a lower IC50 by a factor of 8 in primary cell cultures compared to its 
unprotected hydroxyl equivalent.18 Although hydrogen bonds increase solubility, they must be 
broken for a compound to permeate through the membrane lipid bilayer. Finally, we highlight 
that a further consideration when assessing the effects of glucose analogues in hepatocytes in 
comparison with physiological effectors is that the efficacy of high glucose on GP is in part 
due to the raised cell glucose 6-P which acts synergistically with glucose in stabilizing the T-
state.49-51 
 
Conclusions 
C-β-D-Glucopyranosyl azoles are potent inhibitors of GP and have potential for treatment of 
T2D and inhibition of glycogenolysis in other conditions. New inhibitors have been designed 
and synthesised motivated by in silico predictions. Post-docking MM-GBSA binding affinity 
calculations with tautomeric correction produced excellent performance statistics for a 
congeneric trainings set of 27 ligands. For the first time, MM-GBSA has been demonstrated as 
an effective approach to study GP catalytic site inhibitors. As a result, four new micromolar 
GPIs (5c, 12b, 13a and 13b) have been identified, with 5c the most potent (Ki = 1.97 µM). Ten 
C-β-D-glucopyranosyl azoles, consisting of some of the most potent GP inhibitors known to 
date, were tested for inhibition of glucagon-stimulated glycogenolysis in hepatocytes. Four of 
these, 5a, 5b, 5c and 9d were effective at inhibiting glycogenolysis at low micromolar 
concentrations with 5a (IC50 = 37 µM) and 5b (IC50 = 28 µM) the most efficient. Therefore, 
the most potent purified enzyme GPIs (5a and 5b) were also the most potent inhibitors of 
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glycogenolysis. The calculated pKa (Epik: 6.2; Jaguar 5.5) of the 5a protonated imidazole 
ligand is consistent with passive permeation of the neutral form but with preferred binding at 
GP predicted as the protonated state of the ligand. To summarize, it has been demonstrated that 
linking the structural features and related physicochemical properties of glucopyranosyl type 
GPIs with their potential efficacy at the cellular level can help guide the design of more drug-
like analogues in the future. Log P in particular has been identified as a simple predictable 
parameter that can be readily considered in this regard. Most importantly, the benefits of 
integrating cellular efficacy studies into GP inhibitor design efforts has been demonstrated 
towards the more efficient identification of drug-like compounds. 
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